Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis
Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis
复制标题
DOI：
10.1097/adm.0000000000000287
复制
发表时间：
2017-03-01
影响因子：
5.5
通讯作者：
Sullivan, Carl
中科院分区：
文献类型：
--
作者：
Zheng, Wanhong;Nickasch, Michael;Sullivan, Carl
目的：回顾性审查临床记录，以评估面对面和远程精神病学丁丙诺啡药物辅助治疗（MAT）方案治疗阿片类药物使用障碍在3个结局上的差异：额外物质使用，达到连续30天和90天戒断的平均时间，以及90天和365天的治疗保留率。方法：使用描述性统计分析对参与远程精神病学和基于面对面小组的门诊丁丙诺啡MAT项目的患者（N=100）的病历进行审查和评估。与远程精神病学MAT组相比，面对面MAT组在额外物质使用方面没有显着差异，时间至30天（P=0.09）和禁欲90天（P=0.22），或90天和365天时的保留率（P=0.99）。结论：我们没有发现通过视频会议和面对面的远程精神病学丁丙诺啡MAT干预之间有任何显著的统计学差异，在我们的综合阿片类药物成瘾治疗模型中，针对在额外物质使用方面被诊断为阿片类药物使用障碍的个体进行面部MAT治疗，达到30天和90天戒断的平均时间以及治疗保持率。
Objectives: To retrospectively review clinic records to assess the difference between face-to-face and telepsychiatry buprenorphine medication-assisted treatment ( MAT) programs for the treatment of opioid use disorder on 3 outcomes: additional substance use, average time to achieve 30 and 90 consecutive days of abstinence, and treatment retention rates at 90 and 365 days.Methods: Medical records of patients (N=100) who were participating in telepsychiatry and in face-to-face group-based outpatient buprenorphine MAT programs were reviewed and assessed using descriptive statistical analysis.Results: In comparison with the telepsychiatry MAT group, the faceto- face MAT group showed no significant difference in terms of additional substance use, time to 30 days (P=0.09) and 90 days of abstinence ( P=0.22), or retention rates at 90 and 365 days (P=0.99).Conclusions: We did not find any significant statistical difference between telepsychiatry buprenorphine MAT intervention through videoconference and face-to-face MAT treatment in our Comprehensive Opioid AddictionTreatmentmodel for individuals diagnosed with opioid use disorder in terms of additional substance use, average time to 30 and 90 days of abstinence, and treatment retention rates.